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Statin drugs are a modern success story. They are the
medical treatment for coronary disease and the star of the
pharmaceutical industry. Worldwide, sales of statins are
running at about $19 billion a year and growing quickly.1
This success profits not only the pharmaceutical industry
but also all those whose finances and careers are furthered
by the research and the sales. But to what extent is it also a
success for the general public? To answer this we will look
at the major long-term (five to six year) clinical trials of
statins. We start with the treatment offered to the
participants, then look at the endpoints that were selected,
and continue with a look at how the results have been
reported. We conclude with a discussion of the cost-
effectiveness of statins for people at different levels of risk
of coronary heart disease (CHD).
THE COMPARISON GROUP: BEST CURRENT
TREATMENT OR PLACEBO?
The control groups in all of the trials have been given
placebo pills. A more strenuous comparison, that of the
‘best current prophylactic, diagnostic, and therapeutic
methods,’ was advocated by the World Medical Association
in the Declaration of Helsinki.2 For statins, this is not
another drug but lifestyle factors. The European Athero-
sclerosis Society 1987 guidelines made dietary management
‘the sole therapy for the majority of people with elevated
levels [of blood lipids]’.3 Furthermore, ‘A dietitian,
supported by the patient’s physician, is best able to instruct
the patient, adapt the diet to energy needs and food
preferences, and [if the response is inadequate] to monitor
ongoing compliance.’ A year later the US National
Cholesterol Education Program4 stated:
‘Drug therapy is likely to continue for many years, or for
a lifetime. Hence, the decision to add drug therapy to
the regimen should be made only after vigorous efforts at
dietary treatment have not proven sufficient.’
Vigorous efforts are defined as a minimum of six months
of intensive dietary counselling before starting drug
therapy. This is to occur in two steps. Step one involves
a total fat intake of less than 30% of calories, less than 10%
of which is saturated fat, and less than 300 mg per day of
cholesterol. If that does not bring the blood cholesterol
down to the target level, then a step two diet is initiated
which lowers the intake of saturated fat and cholesterol still
further. ‘Involvement of a dietitian is very useful,
particularly for intensive dietary therapy such as the Step
Two Diet.’4
All of the trials were initiated after the publication of
these guidelines.5–13 What the researchers did instead was
to recommend a step one diet, wait a few weeks—not six
months—and then, if the desired levels of blood cholesterol
were not reached, enrol the patients into the study proper.
Why were these guidelines not followed? Certainly the
initial cost would be greater, but from a public point of
view it would seem advisable since a dietary regimen would
not only help reduce CHD but could have a beneficial result
on several other diseases and save on the costs of multiple
procedures, not just statin drugs.
One thing that might have happened if all participants
had been given dietary intervention before starting statins is
that it would have much reduced the differences in deaths
from CHD and all-cause mortality in the trials (see Table 1).
THE PROBLEM OF ENDPOINTS
A sign of a mature scientific strategy is consistency in the
criteria that are used to measure its success. But one of the
most inconsistent aspects of the statin trials is the choice and
variety of endpoints. Some single-criterion items are found
in some of the trials but not in others, and there is an ever-
growing list of items that are placed in varying combination
with each other. All-cause mortality, the only measure not
prone to diagnostic variance, is not popular. It is not even
reported in a sub-study of the Heart Protection Study (HPS)13
and has to be searched for in several of the other trials.
Combination endpoints are often used—such as death,
myocardial infarction (MI), and stroke—and only the first
event is counted. Most of these combination endpoints are
conceptually inconsistent. Some of the studies add in a
treatment, usually a form of revascularization. Treatments
are arbitrary physician-chosen entities, not instances of
morbidity. Why this huge palette of combination events?
Could it be that the study designers are searching for the
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avoid those that probably will not? This would not be the
scientific approach but would make sense if the aim was to
make the study appear highly successful. A recent review of
167 trials suggests just such a possibility.14 It found that ‘the
inclusion of a clinician-driven outcome was predictive of a
statistically significant result for the primary composite
outcome.’ In other words, the studies would not have
yielded positive results if they had stuck to morbidity
measures.
With respect to data on deaths the most important
endpoint is all-cause mortality. This can be manipulated
only by fraud and is the one of primary concern to the
recipients of the treatment—are they less likely to die soon,
whatever the reason, if they take this drug? Of course, a
detailed breakdown of causes of death must also be
included. For morbidity items, we need to have clear
information on the patient’s quality of life. If a drug or
other intervention neither extends life nor improves its
overall quality, then it is of no value. We need to focus on
these two endpoints and they should be kept separate, not
put together in piecemeal fashion. Regrettably, there is no
rigorous reporting of all-cause morbidity, nor of measure-
ment of changes in overall quality of life, in any of the
studies. Rather, it is assumed that less CHD-related
morbidity leads to less morbidity overall.
Unfortunately, designating all-cause mortality and
overall quality of life as the primary endpoints is not ‘usual
practice’ in the medical research world. Such a shift from a
medical industry perspective to a public benefit perspective
is long overdue.15,16
PRESENTATION OF TRIAL DATA
The statin trials found absolute differences of less than 1%
to a maximum of 3.3% in all-cause mortality between the
control and treatment groups, and from 1.1% to 4.7% in
the most standard combined event, fatal and nonfatal MI.
These are not impressive results. But there is a way of
making them look impressive—namely, by expressing the
results as relative difference rather than as absolute
difference. Take, for example, the LIPID trial.6 It involved
only patients with CHD (i.e. it was a secondary prevention
trial). The difference in deaths between the statin group and
the placebo group was 3.1% (14.1% of the placebo group
died and 11% of the statin group). But the impact of these
results can be much magnified by expressing them as
relative differences: ‘The statin drug lowered the risk of
death by 22%’ (11 is 22% lower than 14.1).
Another serious problem with the way the results are
presented is that the reader is often not told the number
needed to treat (NNT) for one patient to benefit. The
NNTs range from around 30 in the 4S and LIPID trials to
over 100 in the primary prevention trials. But this is not the
information that patients are likely to be given; instead,
they will be told that they will reduce their risk of death by
about 30%. Presenting information to patients in the form
of relative risk will much increase their receptiveness to
taking the drug.
4S and LIPID were secondary prevention trials in
patients with CHD and high cholesterol. Because the
participants were at high risk of death from CHD, the
NNTs are modest. Many such patients, perhaps a majority,
may therefore agree to take statins, even when given an
unbiased version of the efficacy of the drug. But the
situation is altogether different when we turn our attention
to primary trials. Here, the participants have one or more
risk factors for CHD and are therefore at increased risk for
the disease. However, their risk of death from CHD is still
much lower than that of participants in secondary trials. As462
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Table 1 Statin drug trials
All-cause mortality CHD mortality
Trial Type of trial Patients Abs % NNT Abs % NNT
4S (Ref 5) Secondary 3.3 30 3.5 29
LIPID (Ref 6) Secondary 3.1 32 1.9 53
CARE I (Ref 7) Secondary 51 4100 1.1 91
CARE II (Ref 8) Secondary Age 65–75 not reported 51 ?
WOSCOPS (Ref 9) Primary 51 4100 51 4100
ALLHAT-LLT (Ref 10) Primary Hypertension 51 4100 0.0 ?
AFCAPS/TexCAPS (Ref 11) Primary 51 4100 51 4100




35% with type 2 diabetes 1.8 56 1.5 67
Heart Protection Study (sub-study)
(Ref 13)
Mainly primary Type 2 diabetes 2.0 50 2.1 48*
*All vascular caused deaths
CHD=coronary heart disease; Abs %=absolute difference in %; NNT=number needed to treat
indicated in the Table, the NNT for such patients is much
higher, often well over 100. In these circumstances the way
the ‘facts’ are presented is likely to have an enormous
impact on whether the patient agrees to take statins. Does
the doctor say: ‘Mr Smith, if you take statins this will
reduce your risk of dying from heart disease by 30%’? Or
does she say: ‘Mr Smith, if you take statins, then in seven
years’ time there is a one chance in about 120 that your
death will have been prevented’? We argue that the latter is
a much more honest version of the clinical reality.
COST-EFFECTIVENESS OF STATINS
Now let us look at the cost of preventing CHD by using
statins. The simplest, minimum-assumption, calculation is
based on three factors—the cost of the drug per year, the
NNT, and the length of the trials. The two secondary
prevention trials indicate an NNT of about 30 to postpone
one death.5,6 Using this figure and a conservative estimate
of the cost of the statin drugs per year of $500, we arrive at
the cost of postponing one death of $85 500 (50063065.7).
But that figure becomes much higher when we use data
from the primary prevention trials, as the NNTs are much
higher. This has become especially relevant because the
latest NCEP III guidelines have considerably lowered the
eligibility requirements for using statin drugs.17 This was
done by lowering the LDL-C threshold from54.1 mmol/L
to 53.3 mmol/L in conjunction with various risk factors,
some of which were also modified to be more inclusive.
According to a detailed analysis it was estimated that the
new guidelines have the effect of expanding the number of
people in the USA who are now eligible for lipid lowering
by drug therapy, which in most cases means statins, from 15
million to 36 million, a jump of 140% at a stroke.18 It is
noteworthy that the chair of the committee that wrote these
guidelines as well as five of the 13 members of the
committee have received drug company funding. The
European recommendations are very similar, with targets of
5 mmol/L for total cholesterol and 3 mmol/L for LDL.
The effect of widening the net for use of statins means
that millions of people at only modest risk of CHD will be
eligible. For such people the cost will be exceedingly high
for the benefit achieved. We can illustrate this by looking at
a recent estimate. Using data from the HPS trials,
Marshall19 compared the relative cost-effectiveness of
aspirin, hypertension treatment, and a statin. His
calculations were based on costs in the UK and focused
on patients at a 10% risk of experiencing a major coronary
event in the next five years. He estimated that aspirin could
prevent one CHD event (CHD death, angina, MI) for
£3500, compared with £61 400 for statins. Another
important point made by Marshall was that, if patients at
high risk of CHD are given aspirin, then the cost of
preventing a coronary event by also giving statins becomes
much higher than the above figure. This is because, since
the risk of CHD has now been reduced by aspirin, the NNT
for statins has increased, and the cost of preventing a CHD
event with a statin has therefore also much increased. It is
arguable that statins are cost-effective for the small minority
of people at especially high risk of CHD. However, the case
for statins becomes particularly dubious when we consider
the impact of throwing the net wider to include, for
example, people in their fifties whose only risk factor is a
high cholesterol. In North America, the drug companies are
advertising directly to that section of the population, urging
them to ask their doctor for a prescription for statins. For
people at that risk level, the cost of statins translates to
more than $300 000 to prevent a major CHD event. In the
UK National Health Service, statins are at present available
only to people whose global risk is greater than 3% per
year—a figure much influenced by the cost of the drugs and
other pressures on the exchequer. In other European
countries, clinicians have more latitude. This year the UK
Government has tacitly acknowledged a wider demand by
making one of the statins, simvastatin, available without
prescription. Presumably the British public will in due
course be exposed to a direct marketing campaign on North
American lines. The diversion of incomes, whether personal
or national, to such high-cost low-efficacy interventions is
always something to be resisted. What is the opportunity
cost of such expenditure? In national terms the NNT
required to lift a young person out of poverty, thus
resulting in better health and more productivity, is probably
much superior.
CONCLUSIONS
The design of the trials has not involved the testing of the
value of statin drugs relative to that of guideline-
recommended promotion of lifestyle changes. The small
differences favouring the drug have been magnified by the
manner of presentation of results, most notably by the use
of relative differences between statins and placebo groups
rather than absolute differences. A broad societal
perspective is lacking with regard to acceptable costs of
these and other medical interventions. Lowering the
threshold to make much larger numbers of people eligible
for drug therapy has the effect of making statins an
extremely expensive means of preventing heart disease. The
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